Jump to content

Final ASCO today: Cabaxitaxel (Jevtana) looking good, but trial too small to be sure


Admin
 Share

Recommended Posts

In short

It looks like cabazitaxel (Jevtana) might be more useful in metastatic castrate-resistant prostate cancer than abiraterone (Zytiga) or enzalutamide (Xtandi).

However, the clinical trial did not gather enough men to be sure.

So it will be up to the clinical judgment of your specialist.

In Australia, cabazitaxel, is on the PBS after you have had docetaxel chemotherapy.

Details

Dr Jason Zhu gives his account of the report of the trial by Dr Kim Chi here:

https://www.urotoday.com/conference-highlights/asco-2019-annual-meeting/asco-2019-prostate-cancer/112892-asco-2019-updated-results-from-a-randomized-phase-ii-study-of-cabazitaxel-versus-abiraterone-or-enzalutamide-in-poor-prognosis-metastatic-crpc-oncologist-perspective.html

The article is not on this site.

If you click on the link, you will be taken to a site where we do not control the content.

So, please be careful about what you read there, and ask your doctor about anything you read.

You may need to subscribe to the site to view the article.

If it is temporarily or permanently unavailable, you may receive an error message.

Link to comment
Share on other sites

 Share

×
×
  • Create New...